The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation

The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivationThe evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation, Published online: 20 December 2017; doi:10.1038/s41391-017-0014-9The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation

Source: Prostate Cancer and Prostatic Diseases - December 20, 2017 Category: Urology & Nephrology Authors: Megan McNamara Christopher Sweeney Emmanuel S. Antonarakis Andrew J. Armstrong Source Type: research